CN117915923A - 用于治疗内皮病的中分子量肝素 - Google Patents

用于治疗内皮病的中分子量肝素 Download PDF

Info

Publication number
CN117915923A
CN117915923A CN202280045684.XA CN202280045684A CN117915923A CN 117915923 A CN117915923 A CN 117915923A CN 202280045684 A CN202280045684 A CN 202280045684A CN 117915923 A CN117915923 A CN 117915923A
Authority
CN
China
Prior art keywords
molecular weight
weight heparin
vwf
medium molecular
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280045684.XA
Other languages
English (en)
Chinese (zh)
Inventor
P·S·博加尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glicos Biomedical Co ltd
Original Assignee
Glicos Biomedical Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glicos Biomedical Co ltd filed Critical Glicos Biomedical Co ltd
Publication of CN117915923A publication Critical patent/CN117915923A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202280045684.XA 2021-05-14 2022-05-16 用于治疗内皮病的中分子量肝素 Pending CN117915923A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB2106972.9 2021-05-14
GBGB2106972.9A GB202106972D0 (en) 2021-05-14 2021-05-14 Medium molecular weight heparin
PCT/EP2022/063222 WO2022238587A1 (en) 2021-05-14 2022-05-16 Medium molecular weight heparin for use in the treatment of endotheliopathy

Publications (1)

Publication Number Publication Date
CN117915923A true CN117915923A (zh) 2024-04-19

Family

ID=76550734

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280045684.XA Pending CN117915923A (zh) 2021-05-14 2022-05-16 用于治疗内皮病的中分子量肝素

Country Status (8)

Country Link
US (1) US20240245718A1 (https=)
EP (1) EP4337225A1 (https=)
JP (1) JP2024517355A (https=)
CN (1) CN117915923A (https=)
AU (1) AU2022273186A1 (https=)
CA (1) CA3219993A1 (https=)
GB (1) GB202106972D0 (https=)
WO (1) WO2022238587A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025106117A1 (en) * 2023-11-17 2025-05-22 Glycos Biomedical Ltd. Medium molecular weight heparin
GB202407360D0 (en) * 2024-05-23 2024-07-10 Glycos Biomedical Ltd Functionalised medium molecular weight heparin

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ20014665A3 (cs) * 1999-06-30 2002-05-15 Hamilton Civic Hospitals Research Development, Inc Prostředek s obsahem heparinu se střední molekulovou hmotností
EP3348270A1 (en) * 2017-01-11 2018-07-18 Fytagoras B.V. Medium molecular weight heparin
JP2021155334A (ja) * 2018-05-01 2021-10-07 学校法人近畿大学 中分子ヘパリンまたは中分子ヘパリンのアミノ酸誘導体を含む医薬組成物
WO2022016098A1 (en) * 2020-07-17 2022-01-20 Xostem Ip, Inc. Compositions and methods for treatment of inflammatory and thromboinflammatory disorders using modified exosomes

Also Published As

Publication number Publication date
GB202106972D0 (en) 2021-06-30
EP4337225A1 (en) 2024-03-20
US20240245718A1 (en) 2024-07-25
WO2022238587A1 (en) 2022-11-17
JP2024517355A (ja) 2024-04-19
AU2022273186A1 (en) 2024-01-04
CA3219993A1 (en) 2022-11-17

Similar Documents

Publication Publication Date Title
Best et al. The efficacy and safety of short-and long-term dual antiplatelet therapy in patients with mild or moderate chronic kidney disease: results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial
Gamboa et al. Comparative effects of angiotensin-converting enzyme inhibition and angiotensin-receptor blockade on inflammation during hemodialysis
Thielmann et al. Administration of C1-esterase inhibitor during emergency coronary artery bypass surgery in acute ST-elevation myocardial infarction
CN117915923A (zh) 用于治疗内皮病的中分子量肝素
Garantziotis et al. Serum inter–α-trypsin inhibitor and matrix hyaluronan promote angiogenesis in fibrotic lung injury
Rikken et al. Prepercutaneous coronary intervention Zalunfiban dose-response relationship to target vessel blood flow at initial angiogram in st-elevation myocardial infarction–A post hoc analysis of the cel-02 phase IIa study
Jankowska-Sanetra et al. Incidence and course of acute coronary syndrome cases after the first wave of the COVID-19 pandemic
Koganei et al. Association of glomerular filtration rate with unsuccessful primary percutaneous coronary intervention and subsequent mortality in patients with acute myocardial infarction from the HIJAMI Registry
WO2024105271A1 (en) Preparation of medium molecular weight heparin
Hobbach et al. The prognostic value of serum creatinine on admission in fibrinolytic-eligible patients with acute myocardial infarction
Ekholm et al. Alterations in platelet activity and endothelial glycocalyx biomarkers by treatment with an angiotensin converting enzyme inhibitor or an alpha-1 adrenoceptor antagonist in patients with hypertension: results from the DoRa study
HK40109661A (zh) 用於治疗内皮病的中分子量肝素
Chandiramani et al. Protamine-induced coronary graft thrombosis: A review
JP2025537781A (ja) 中間分子量ヘパリンの調製
Kon et al. Warm ischemia provokes inflammation and regional hypercoagulability within the heart during off-pump coronary artery bypass: a possible target for serine protease inhibition
WO2025106117A1 (en) Medium molecular weight heparin
Shi et al. Effect of statins combined with PCSK9 inhibitors on the prognosis of patients with acute coronary syndromes after interventional therapy
Afshari Evidence based evaluation of immuno-coagulatory interventions in critical care
Brodin et al. Intravascular release and urinary excretion of tissue factor pathway inhibitor during heparin treatment
Ngu et al. Use of anticoagulants in COVID-19: a review
WO2025245445A1 (en) Functionalised medium molecular weight heparin
Goubran et al. Coagulation and Anticoagulants
Oldgren et al. Xa inhibition and coagulation activity—the influence of prolonged dalteparin treatment and gender in patients with acute coronary syndrome and healthy individuals
Tuncay et al. The Effect of Contrast Agents on the Anticoagulant Properties of Oral Factor Xa Inhibitors
Özkan et al. Acute complications of hemodialysis

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40109661

Country of ref document: HK